Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Revive Meds vs Shapely

Revive Meds
Graded #405

Lower grade

vs+8.500000000000007
Shapely
Graded #225

Higher grade

The verdict

Shapely takes it — 65.4/100 to 56.9/100.

Shapely grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Shapely is a GLP-1 telehealth platform founded by Dr.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueShapely +24
21
45
Dose & formulationRevive Meds +11
64
53
Clinical oversightShapely +14
80
94
Labs & monitoringShapely +21
52
73
FulfillmentRevive Meds +12
90
78
Contract termsShapely +2
53
55
Revive Meds · left barShapely · right bar

The numbers

MetricRevive MedsShapely
WeighScore56.9/10065.4/100
GradeCC
Scorecard rank#405#225
Semaglutide$369/mo (starting dose, compounded)Not disclosed
Tirzepatide$459/mo (starting dose, compounded)Not disclosed
CoverageAll 50 states4 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Revive Meds

Graded #405 · C

Strengths

  • Offers both compounded semaglutide and dual-agonist tirzepatide, each combined with vitamin B12 (cyanocobalamin) in a single injection
  • Pay-per-order model with no subscription, sign-up fees, or long-term commitment, and free shipping on every order
  • Names its six 503A compounding pharmacies and two prescribing physicians, which is unusually transparent on fulfillment
  • Available in all 50 states and HSA/FSA eligible through a Medical Necessity Letter
  • Prepaying 3 to 12 months cuts the effective cost to as low as $202/mo (semaglutide) or $300/mo (tirzepatide)

Where it loses points

  • Month-to-month pricing is steep: $369/mo semaglutide and $459/mo tirzepatide unless you prepay several months
  • No public price list; pricing appears only after you complete a full health intake and create an account
  • Not LegitScript-certified (no seal displayed on the site)
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Shapely

Graded #225 · C

Strengths

  • Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
  • Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
  • Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
  • 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
  • Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program

Where it loses points

  • Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
  • Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
  • Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
  • No LegitScript certification found on any public page
  • Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard